NewswireToday - /newswire/ -
Delhi, New Delhi, India, 2007/03/27 - Be it population or technology, India is all set to outshine China. The next subject for competition is biotech hectares where India has left China much behind.
Clive James, Chairman, International Service for the Acquisition of Agri-biotech Applications (ISAAA), said in a statement as reported on February 20, 2007 by checkbiotech.org that India is fast evolving as a leading biotech region in Asia, outshining China for the first time in terms of total hectare land planted with biotechnology seeds.
In 2006, India’s area planted with biotech cotton grew triple-fold (India’s first commercialized biotech crop) from the last year. The total biotech hectare in India now stands at an impressive 3.8 million as against 3.5 million in China.
Quality seeds with good biotechnology are making the rise in productivity of Indian cultivators stronger.
After biotech cotton, the next major crop to be traded in the Asian market will be ‘golden rice’. This variety of rice is fortified with Vitamin A - essential for vision, and the intestinal, urinary, and respiratory tracts.
The biotech development is immensely important for agriculture as a whole as researchers search for ways to make a variety of crops better. Biotechnology is an important tool being rapidly adapted and used by farmers in developing countries and is greatly influencing the countries’ development and thereby, their economy.
Asian cultivators have adopted GM (genetically modified) crops that are insect-resistant, pest-resistant, and have many other additional benefits. Countries like India are making huge investments in the research of agricultural biotechnology to meet their surging needs for food, fuel, and fiber.
India is expected to develop a national chain of research laboratories by infusing $80 Million in 2007.
According to the RNCOS report “Indian Biotechnology Market Outlook (2006)”, biotech will greatly influence the Indian agriculture sector by developing a large number of GM seeds. Amplifying at the rate of 28.09% from 2005, the Indian biotech industry is believed to reach the level of US$ 5 Billion by 2010 end.
The market research report also discusses the position of Indian biotech sector with respect to Asia-Pacific region, and its market performance. The report gives a detailed account of agri biotech in the country supported by statistical data. It provides an insight into the market size, domestic and exports market, and market segmentation covering vaccines, biogenerics, therapeutics, etc. Investment scenario, employment opportunities, government initiatives and regulatory environment have been given in detail for investors.
RNCOS, incorporated in the year 2002, is an industry research firm. It has a team of industry experts who analyze data collected from credible sources. They provide industry insights and analysis that helps corporations to take timely and accurate business decision in today's globally competitive environment.